{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:51:02Z","timestamp":1791827462756,"version":"4.3.4"},"reference-count":242,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Probecell Scientific Pvt. Ltd.","award":["Probecell\/Res\/2026\/124"],"award-info":[{"award-number":["Probecell\/Res\/2026\/124"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-026-02383-7","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:27:14Z","timestamp":1791826034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR\/Cas9-based nanodelivery systems for precision gene editing in neuroinflammation"],"prefix":"10.1007","volume":"75","author":[{"given":"Sanjana","family":"Sahu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan Kumar","family":"Dharme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2383_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/FGENE.2021.673286","author":"L Duan","year":"2021","unstructured":"Duan L, et al. Nanoparticle Delivery of CRISPR\/Cas9 for genome-editing. Front Genet. 2021. https:\/\/doi.org\/10.3389\/FGENE.2021.673286.","journal-title":"Front Genet"},{"key":"2383_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-01906-8","author":"A Patel","year":"2025","unstructured":"Patel A, Jain P. Recent advances in the therapeutics and modes of action of a range of agents used to treat ulcerative colitis and related inflammatory conditions. Inflammopharmacology. 2025. https:\/\/doi.org\/10.1007\/s10787-025-01906-8.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"2383_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1023\/B:HREV.0000011393.40674.13","volume":"9","author":"DA Siwik","year":"2004","unstructured":"Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen\/nitrogen species in the myocardium. Heart Fail Rev. 2004;9(1):43\u201351. https:\/\/doi.org\/10.1023\/B:HREV.0000011393.40674.13.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"2383_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.65807\/prob.sci.2026.3.1.2","volume":"3","author":"N Yadav","year":"2026","unstructured":"Yadav N, Jain P, Prasad J. Nanoparticle-mediated quercetin delivery mitigates oxidative stress in diabetic neuropathy in experimental animals. Probecell Sci. 2026;3(1):11\u201323. https:\/\/doi.org\/10.65807\/prob.sci.2026.3.1.2.","journal-title":"Probecell Sci"},{"issue":"1","key":"2383_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S41984-022-00150-4","volume":"37","author":"L Hanna","year":"2022","unstructured":"Hanna L, Poluyi E, Ikwuegbuenyi C, Morgan E, Imaguezegie G. Peripheral inflammation and neurodegeneration; a potential for therapeutic intervention in alzheimer\u2019s disease (AD), parkinson\u2019s disease (PD) and amyotrophic lateral sclerosis (ALS). Egypt J Neurosurg. 2022;37(1):1\u20139. https:\/\/doi.org\/10.1186\/S41984-022-00150-4.","journal-title":"Egypt J Neurosurg"},{"issue":"8","key":"2383_CR6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/J.IT.2008.05.002","volume":"29","author":"HM Gao","year":"2008","unstructured":"Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008;29(8):357\u201365. https:\/\/doi.org\/10.1016\/J.IT.2008.05.002.","journal-title":"Trends Immunol"},{"key":"2383_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/FNAGI.2024.1347987","author":"A Adamu","year":"2024","unstructured":"Adamu A, Li S, Gao F, Xue G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front Aging Neurosci. 2024. https:\/\/doi.org\/10.3389\/FNAGI.2024.1347987.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"2383_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/J.GENDIS.2023.03.017","volume":"11","author":"H Jiang","year":"2024","unstructured":"Jiang H, et al. CRISPR\/Cas9 system and its applications in nervous system diseases. Genes Dis. 2024;11(2):675\u201386. https:\/\/doi.org\/10.1016\/J.GENDIS.2023.03.017.","journal-title":"Genes Dis"},{"issue":"1","key":"2383_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.gendis.2023.02.027","volume":"11","author":"M Khoshandam","year":"2024","unstructured":"Khoshandam M, Soltaninejad H, Mousazadeh M, Hamidieh AA, Hosseinkhani S. Clinical applications of the CRISPR\/Cas9 genome-editing system: delivery options and challenges in precision medicine. Genes Dis. 2024;11(1):268\u201382. https:\/\/doi.org\/10.1016\/j.gendis.2023.02.027.","journal-title":"Genes Dis"},{"key":"2383_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIOX14070781","author":"I Raffaele","year":"2025","unstructured":"Raffaele I, Cipriano GL, Anchesi I, Oddo S, Silvestro S. CRISPR\/Cas9 and iPSC-based therapeutic approaches in alzheimer\u2019s disease. Antioxidants. 2025. https:\/\/doi.org\/10.3390\/ANTIOX14070781.","journal-title":"Antioxidants"},{"key":"2383_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.17179\/EXCLI2023-6155","volume":"22","author":"JN Nojadeh","year":"2023","unstructured":"Nojadeh JN, Ery\u0131lmaz NSB, Erg\u00fcder B\u0130. CRISPR\/Cas9 genome-editing for neurodegenerative diseases. EXCLI J. 2023;22:567\u201382. https:\/\/doi.org\/10.17179\/EXCLI2023-6155.","journal-title":"EXCLI J"},{"key":"2383_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/S11011-025-01564-3","author":"M Hassanzadeh-khanmiri","year":"2025","unstructured":"Hassanzadeh-khanmiri M, et al. Nanomedicine: a cost-effective and powerful platform for managing neurodegenerative diseases. Metab Brain Dis. 2025. https:\/\/doi.org\/10.1007\/S11011-025-01564-3.","journal-title":"Metab Brain Dis"},{"key":"2383_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/BTT.S326422","volume":"15","author":"MA Mengstie","year":"2021","unstructured":"Mengstie MA, Wondimu BZ. Mechanism and applications of CRISPR\/Cas-9-mediated genome-editing. Biologics. 2021;15:353\u201361. https:\/\/doi.org\/10.2147\/BTT.S326422.","journal-title":"Biologics"},{"issue":"5","key":"2383_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcyt.2024.02.014","volume":"26","author":"P Kavousinia","year":"2024","unstructured":"Kavousinia P, Ahmadi MH, Sadeghian H, Hosseini Bafghi M. Therapeutic potential of CRISPR\/CAS9 genome modification in T cell-based immunotherapy of cancer. Cytotherapy. 2024;26(5):436\u201343. https:\/\/doi.org\/10.1016\/j.jcyt.2024.02.014.","journal-title":"Cytotherapy"},{"key":"2383_CR15","doi-asserted-by":"publisher","DOI":"10.1098\/RSTB.2015.0496","author":"F Hille","year":"2016","unstructured":"Hille F, Charpentier E. CRISPR-Cas: biology, mechanisms and relevance. Philos Trans R Soc B Biol Sci. 2016. https:\/\/doi.org\/10.1098\/RSTB.2015.0496.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"2383_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.biochi.2015.03.025","volume":"117","author":"D Rath","year":"2015","unstructured":"Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: biology, mechanisms and applications. Biochimie. 2015;117:119\u201328. https:\/\/doi.org\/10.1016\/j.biochi.2015.03.025.","journal-title":"Biochimie"},{"issue":"11","key":"2383_CR17","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/NPROT.2013.143;SUBJMETA","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR\/Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308. https:\/\/doi.org\/10.1038\/NPROT.2013.143;SUBJMETA.","journal-title":"Nat Protoc"},{"issue":"9\u201310","key":"2383_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/S00335-015-9565-Z\/TABLES\/2","volume":"26","author":"MV Wiles","year":"2015","unstructured":"Wiles MV, Qin W, Cheng AW, Wang H. CRISPR\u2013Cas9-mediated genome-editing and guide RNA design. Mamm Genome. 2015;26(9\u201310):501\u201310. https:\/\/doi.org\/10.1007\/S00335-015-9565-Z\/TABLES\/2.","journal-title":"Mamm Genome"},{"issue":"12","key":"2383_CR19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.tplants.2019.09.006","volume":"24","author":"H Manghwar","year":"2019","unstructured":"Manghwar H, Lindsey K, Zhang X, Jin S. CRISPR\/Cas system: recent advances and future prospects for genome-editing. Trends Plant Sci. 2019;24(12):1102\u201325. https:\/\/doi.org\/10.1016\/j.tplants.2019.09.006.","journal-title":"Trends Plant Sci"},{"issue":"7","key":"2383_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/J.TIG.2021.02.008","volume":"37","author":"C Xue","year":"2021","unstructured":"Xue C, Greene EC. DNA repair pathway choices in CRISPR\/Cas9 -mediated genome-editing. Trends Genet. 2021;37(7):639\u201356. https:\/\/doi.org\/10.1016\/J.TIG.2021.02.008.","journal-title":"Trends Genet"},{"issue":"6096","key":"2383_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/SCIENCE.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816\u201321. https:\/\/doi.org\/10.1126\/SCIENCE.1225829.","journal-title":"Science"},{"issue":"4","key":"2383_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/ARCHDISCHILD-2016-310459","volume":"101","author":"M Redman","year":"2016","unstructured":"Redman M, King A, Watson C, King D. What is CRISPR\/Cas9? Arch Dis Child Educ Pract Ed. 2016;101(4):213\u20135. https:\/\/doi.org\/10.1136\/ARCHDISCHILD-2016-310459.","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"2383_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2021.699597","author":"SA Abdelnour","year":"2021","unstructured":"Abdelnour SA, Xie L, Hassanin AA, Zuo E, Lu Y. The potential of CRISPR\/Cas9 gene editing as a treatment strategy for inherited diseases. Front cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/FCELL.2021.699597.","journal-title":"Front cell Dev Biol"},{"issue":"21","key":"2383_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2217\/EPI-2023-0281","volume":"15","author":"SM Fadul","year":"2023","unstructured":"Fadul SM, Arshad A, Mehmood R. CRISPR-based epigenome-editing: mechanisms and applications. Epigenomics. 2023;15(21):1137\u201355. https:\/\/doi.org\/10.2217\/EPI-2023-0281.","journal-title":"Epigenomics"},{"key":"2383_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1849543520983196","author":"J Padayachee","year":"2020","unstructured":"Padayachee J, Singh M. Therapeutic applications of CRISPR\/Cas9 in breast cancer and delivery potential of gold nanomaterials. Nanobiomedicine. 2020. https:\/\/doi.org\/10.1177\/1849543520983196.","journal-title":"Nanobiomedicine"},{"key":"2383_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/S40164-024-00570-Y","author":"X Feng","year":"2024","unstructured":"Feng X, Li Z, Liu Y, Chen D, Zhou Z. CRISPR\/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications. Exp Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/S40164-024-00570-Y.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"2383_CR27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1523\/ENEURO.0448-18.2019","volume":"6","author":"T Kaiser","year":"2019","unstructured":"Kaiser T, Feng G. Tmem119-EGFP and Tmem119-CreERT2 transgenic mice for labeling and manipulating microglia. eNeuro. 2019;6(4):448.","journal-title":"eNeuro"},{"key":"2383_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101135","author":"JR Lydeard","year":"2023","unstructured":"Lydeard JR, et al. Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity. Mol Ther Methods Clin Dev. 2023. https:\/\/doi.org\/10.1016\/j.omtm.2023.101135.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2383_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/BIOM13020324","author":"S Sellaththurai","year":"2023","unstructured":"Sellaththurai S, et al. CRISPR\/Cas9-induced knockout of sting increases susceptibility of zebrafish to bacterial infection. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/BIOM13020324.","journal-title":"Biomolecules"},{"issue":"2","key":"2383_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3324\/HAEMATOL.2022.280786","volume":"108","author":"ME Lalonde","year":"2023","unstructured":"Lalonde ME, et al. Genome-wide CRISPR screens identify ferroptosis as a novel therapeutic vulnerability in acute lymphoblastic leukemia. Haematologica. 2023;108(2):382\u201393. https:\/\/doi.org\/10.3324\/HAEMATOL.2022.280786.","journal-title":"Haematologica"},{"issue":"1","key":"2383_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/NCHEMBIO.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91\u20138. https:\/\/doi.org\/10.1038\/NCHEMBIO.2239.","journal-title":"Nat Chem Biol"},{"key":"2383_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/S13024-019-0321-9","author":"W Yang","year":"2019","unstructured":"Yang W, Li S, Li XJ. A CRISPR monkey model unravels a unique function of PINK1 in primate brains. Mol Neurodegener. 2019. https:\/\/doi.org\/10.1186\/S13024-019-0321-9.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"2383_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/NAR\/GKZ1136","volume":"48","author":"B Liu","year":"2020","unstructured":"Liu B, et al. Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR\/Cas9 genome-editing. Nucleic Acids Res. 2020;48(2):517\u201332. https:\/\/doi.org\/10.1093\/NAR\/GKZ1136.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2383_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/S40164-025-00609-8","volume":"14","author":"Y Kim","year":"2025","unstructured":"Kim Y, Jeun M, Lee HK, Choi JU, Park S, Park CH. TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model. Exp Hematol Oncol. 2025;14(1):23. https:\/\/doi.org\/10.1186\/S40164-025-00609-8.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2383_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-022-00391-5","volume":"8","author":"Y Wei","year":"2022","unstructured":"Wei Y, et al. Mitochondrial base editor DdCBE causes substantial DNA off-target editing in nuclear genome of embryos. Cell Discov. 2022;8(1):27. https:\/\/doi.org\/10.1038\/s41421-022-00391-5.","journal-title":"Cell Discov"},{"issue":"7817","key":"2383_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/S41586-020-2477-4","volume":"583","author":"BY Mok","year":"2020","unstructured":"Mok BY, et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020;583(7817):631\u20137. https:\/\/doi.org\/10.1038\/S41586-020-2477-4.","journal-title":"Nature"},{"issue":"3","key":"2383_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMOA2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, et al. CRISPR\/Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia. N Engl J Med. 2021;384(3):252\u201360. https:\/\/doi.org\/10.1056\/NEJMOA2031054.","journal-title":"N Engl J Med"},{"issue":"7587","key":"2383_CR38","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/NATURE16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver BP, et al. High-fidelity CRISPR\/Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490\u20135. https:\/\/doi.org\/10.1038\/NATURE16526.","journal-title":"Nature"},{"issue":"6","key":"2383_CR39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/S11248-018-0096-8","volume":"27","author":"CH Lau","year":"2018","unstructured":"Lau CH, Suh Y. In vivo epigenome-editing and transcriptional modulation using CRISPR technology. Transgenic Res. 2018;27(6):489\u2013509. https:\/\/doi.org\/10.1007\/S11248-018-0096-8.","journal-title":"Transgenic Res"},{"issue":"22","key":"2383_CR40","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"PJ Chen","year":"2021","unstructured":"Chen PJ, et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 2021;184(22):5635-5652.e29. https:\/\/doi.org\/10.1016\/j.cell.2021.09.018.","journal-title":"Cell"},{"key":"2383_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2022.100329","author":"R Bi","year":"2022","unstructured":"Bi R, et al. Direct evidence of CRISPR\/Cas9 -mediated mitochondrial genome-editing. Innovation. 2022. https:\/\/doi.org\/10.1016\/j.xinn.2022.100329.","journal-title":"Innovation"},{"key":"2383_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mib.2017.05.008","volume":"37","author":"EV Koonin","year":"2017","unstructured":"Koonin EV, Makarova KS, Zhang F. Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. 2017;37:67\u201378. https:\/\/doi.org\/10.1016\/j.mib.2017.05.008.","journal-title":"Curr Opin Microbiol"},{"key":"2383_CR43","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu Y, Li Z. CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy. Comput Struct Biotechnol J. 2020;18:2401\u201315. https:\/\/doi.org\/10.1016\/j.csbj.2020.08.031.","journal-title":"Comput Struct Biotechnol J"},{"key":"2383_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/DIAGNOSTICS12102455","author":"J Li","year":"2022","unstructured":"Li J, et al. Application of CRISPR\/Cas systems in the nucleic acid detection of infectious diseases. Diagnostics. 2022. https:\/\/doi.org\/10.3390\/DIAGNOSTICS12102455.","journal-title":"Diagnostics"},{"issue":"19","key":"2383_CR45","doi-asserted-by":"publisher","first-page":"13284","DOI":"10.1074\/jbc.M113.539726","volume":"289","author":"H Chen","year":"2014","unstructured":"Chen H, Choi J, Bailey S. Cut site selection by the two nuclease domains of the Cas9 RNA-guided endonuclease. J Biol Chem. 2014;289(19):13284\u201394. https:\/\/doi.org\/10.1074\/jbc.M113.539726.","journal-title":"J Biol Chem"},{"issue":"1","key":"2383_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","volume":"26","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi R, Rondinelli B, D\u2019Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016;26(1):52\u201364. https:\/\/doi.org\/10.1016\/j.tcb.2015.07.009.","journal-title":"Trends Cell Biol"},{"key":"2383_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112743","author":"S Najafi","year":"2022","unstructured":"Najafi S, et al. Therapeutic potentials of CRISPR-Cas genome-editing technology in human viral infections. Biomed Pharmacother. 2022. https:\/\/doi.org\/10.1016\/j.biopha.2022.112743.","journal-title":"Biomed Pharmacother"},{"key":"2383_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/S13578-018-0255-X","author":"Y Tang","year":"2018","unstructured":"Tang Y, Fu Y. Class 2 CRISPR\/Cas: an expanding biotechnology toolbox for and beyond genome-editing. Cell Biosci. 2018. https:\/\/doi.org\/10.1186\/S13578-018-0255-X.","journal-title":"Cell Biosci"},{"issue":"5","key":"2383_CR49","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/J.CELL.2014.02.001","volume":"156","author":"H Nishimasu","year":"2014","unstructured":"Nishimasu H, et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 2014;156(5):935\u201349. https:\/\/doi.org\/10.1016\/J.CELL.2014.02.001.","journal-title":"Cell"},{"issue":"3","key":"2383_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.11613\/BM.2023.030601","volume":"33","author":"Y Khlidj","year":"2023","unstructured":"Khlidj Y. What did CRISPR-Cas9 accomplish in its first 10 years? Biochem med. 2023;33(3):283\u201394. https:\/\/doi.org\/10.11613\/BM.2023.030601.","journal-title":"Biochem med"},{"issue":"2","key":"2383_CR51","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v3i2.184","volume":"3","author":"AN Ansori","year":"2023","unstructured":"Ansori AN, et al. Application of CRISPR-Cas9 genome editing technology in various fields: a review. Narra J. 2023;3(2):e184. https:\/\/doi.org\/10.52225\/narra.v3i2.184.","journal-title":"Narra J"},{"issue":"5","key":"2383_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051288","volume":"9","author":"P Sledzinski","year":"2020","unstructured":"Sledzinski P, Nowaczyk M, Olejniczak M. Computational tools and resources supporting CRISPR-Cas experiments. Cells. 2020;9(5):1288. https:\/\/doi.org\/10.3390\/cells9051288.","journal-title":"Cells"},{"key":"2383_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2023.108317","volume":"213","author":"F Bigini","year":"2023","unstructured":"Bigini F, Lee SH, Sun YJ, Sun Y, Mahajan VB. Unleashing the potential of CRISPR multiplexing: Harnessing Cas12 and Cas13 for precise gene modulation in eye diseases. Vision Res. 2023;213:108317. https:\/\/doi.org\/10.1016\/j.visres.2023.108317.","journal-title":"Vision Res"},{"issue":"8","key":"2383_CR54","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/genes16080875","volume":"16","author":"X Tan","year":"2025","unstructured":"Tan X, et al. CRISPR\/Cas13-Based Anti-RNA Viral Approaches. Genes. 2025;16(8):875. https:\/\/doi.org\/10.3390\/genes16080875.","journal-title":"Genes"},{"key":"2383_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-022-29202-X","author":"AR Krysler","year":"2022","unstructured":"Krysler AR, Cromwell CR, Tu T, Jovel J, Hubbard BP. Guide RNAs containing universal bases enable Cas9\/Cas12a recognition of polymorphic sequences. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/S41467-022-29202-X.","journal-title":"Nat Commun"},{"issue":"45","key":"2383_CR56","doi-asserted-by":"publisher","first-page":"16028","DOI":"10.1021\/JACS.7B05313\/SUPPL_FILE\/JA7B05313_SI_002.MPG","volume":"139","author":"G Palermo","year":"2017","unstructured":"Palermo G, et al. Protospacer Adjacent Motif-Induced Allostery Activates CRISPR\/Cas9. J Am Chem Soc. 2017;139(45):16028\u201331. https:\/\/doi.org\/10.1021\/JACS.7B05313\/SUPPL_FILE\/JA7B05313_SI_002.MPG.","journal-title":"J Am Chem Soc"},{"issue":"4","key":"2383_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/NBT.2842","volume":"32","author":"JD Sander","year":"2014","unstructured":"Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014;32(4):347\u201350. https:\/\/doi.org\/10.1038\/NBT.2842.","journal-title":"Nat Biotechnol"},{"issue":"17","key":"2383_CR58","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1111\/FEBS.13777","volume":"283","author":"SE Mohr","year":"2016","unstructured":"Mohr SE, Hu Y, Ewen-Campen B, Housden BE, Viswanatha R, Perrimon N. CRISPR guide RNA design for research applications. FEBS J. 2016;283(17):3232\u20138. https:\/\/doi.org\/10.1111\/FEBS.13777.","journal-title":"FEBS J"},{"issue":"4","key":"2383_CR59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/S41423-025-01275-W;SUBJMETA","volume":"22","author":"W Xu","year":"2025","unstructured":"Xu W, Huang Y, Zhou R. NLRP3 inflammasome in neuroinflammation and central nervous system diseases. Cell Mol Immunol. 2025;22(4):341\u201355. https:\/\/doi.org\/10.1038\/S41423-025-01275-W;SUBJMETA.","journal-title":"Cell Mol Immunol"},{"key":"2383_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-020-19227-5","author":"A McQuade","year":"2020","unstructured":"McQuade A, et al. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer\u2019s disease. Nat Commun. 2020. https:\/\/doi.org\/10.1038\/S41467-020-19227-5.","journal-title":"Nat Commun"},{"issue":"1","key":"2383_CR61","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/NRD.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78. https:\/\/doi.org\/10.1038\/NRD.2017.267.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2383_CR62","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/S41577-021-00524-Z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21(9):548\u201369. https:\/\/doi.org\/10.1038\/S41577-021-00524-Z.","journal-title":"Nat Rev Immunol"},{"issue":"no. 2","key":"2383_CR63","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","volume":"vol. 29","author":"G Sharma","year":"2021","unstructured":"Sharma G, Sharma AR, Bhattacharya M, Lee SS, Chakraborty C. CRISPR\/Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol Ther. 2021;29(2):571\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.028.","journal-title":"Mol Ther"},{"issue":"2","key":"2383_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/CRISPR.2017.0016","volume":"1","author":"MC Canver","year":"2018","unstructured":"Canver MC, Joung JK, Pinello L. Impact of Genetic Variation on CRISPR-Cas Targeting. Cris J. 2018;1(2):159\u201370. https:\/\/doi.org\/10.1089\/CRISPR.2017.0016.","journal-title":"Cris J"},{"issue":"42","key":"2383_CR65","doi-asserted-by":"publisher","first-page":"44061","DOI":"10.18632\/ONCOTARGET.6392","volume":"6","author":"S Valletta","year":"2015","unstructured":"Valletta S, et al. ASXL1 mutation correction by CRISPR\/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts. Oncotarget. 2015;6(42):44061\u201371. https:\/\/doi.org\/10.18632\/ONCOTARGET.6392.","journal-title":"Oncotarget"},{"key":"2383_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2021.803894","author":"L Lu","year":"2021","unstructured":"Lu L, Yu X, Cai Y, Sun M, Yang H. Application of CRISPR\/Cas9 in alzheimer\u2019s disease. Front Neurosci. 2021. https:\/\/doi.org\/10.3389\/FNINS.2021.803894.","journal-title":"Front Neurosci"},{"key":"2383_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/SCIADV.AAR3952","author":"T Gaj","year":"2017","unstructured":"Gaj T, Ojala DS, Ekman FK, Byrne LC, Limsirichai P, Schaffer DV. In vivo genome-editing improves motor function and extends survival in a mouse model of ALS. Sci Adv. 2017. https:\/\/doi.org\/10.1126\/SCIADV.AAR3952.","journal-title":"Sci Adv"},{"key":"2383_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2020.566858","volume":"14","author":"P Rojas","year":"2020","unstructured":"Rojas P, et al. Amyotrophic lateral sclerosis: a neurodegenerative motor neuron disease with ocular involvement. Front Neurosci. 2020;14:566858. https:\/\/doi.org\/10.3389\/FNINS.2020.566858.","journal-title":"Front Neurosci"},{"issue":"8","key":"2383_CR69","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/J.CELREP.2015.02.002","volume":"10","author":"BJ Aubrey","year":"2015","unstructured":"Aubrey BJ, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10(8):1422\u201332. https:\/\/doi.org\/10.1016\/J.CELREP.2015.02.002.","journal-title":"Cell Rep"},{"issue":"2","key":"2383_CR70","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","volume":"29","author":"G Sharma","year":"2021","unstructured":"Sharma G, Sharma AR, Bhattacharya M, Lee SS, Chakraborty C. CRISPR\/Cas9: a preclinical and clinical perspective for the treatment of human diseases. Mol Ther. 2021;29(2):571\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.028.","journal-title":"Mol Ther"},{"issue":"8","key":"2383_CR71","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/J.MPSUR.2021.06.012","volume":"39","author":"PJ Bazira","year":"2021","unstructured":"Bazira PJ. An overview of the nervous system. Surg. 2021;39(8):451\u201362. https:\/\/doi.org\/10.1016\/J.MPSUR.2021.06.012.","journal-title":"Surg"},{"issue":"4293","key":"2383_CR72","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1136\/bmj.1.4293.478","volume":"1","author":"L Thau","year":"2022","unstructured":"Thau L, Reddy V, Singh P. Anatomy, central nervous system. BMJ. 2022;1(4293):478\u2013478. https:\/\/doi.org\/10.1136\/bmj.1.4293.478.","journal-title":"BMJ"},{"key":"2383_CR73","unstructured":"Anderson BW, Kortz MW, Black AC and Al Kharazi KA. \u201cAnatomy, head and neck, skull\u201d. StatPearls, 2023, Accessed: Sep. 15, 2025. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499834\/"},{"key":"2383_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/DVG.23288","author":"K Dasgupta","year":"2019","unstructured":"Dasgupta K, Jeong J. Developmental biology of the meninges. Genesis. 2019. https:\/\/doi.org\/10.1002\/DVG.23288.","journal-title":"Genesis"},{"key":"2383_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES11051461","author":"N Czarniak","year":"2023","unstructured":"Czarniak N, Kami\u0144ska J, Matowicka-Karna J, Koper-Lenkiewicz OM. Cerebrospinal fluid-basic concepts review. Biomedicines Basel. 2023. https:\/\/doi.org\/10.3390\/BIOMEDICINES11051461.","journal-title":"Biomedicines Basel"},{"issue":"1","key":"2383_CR76","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/S41392-023-01481-W","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: structure, regulation and drug delivery. Signal Transduct Target Ther. 2023;8(1):217. https:\/\/doi.org\/10.1038\/S41392-023-01481-W.","journal-title":"Signal Transduct Target Ther"},{"key":"2383_CR77","doi-asserted-by":"publisher","DOI":"10.1126\/SCIADV.ABM8011","author":"Y Zou","year":"2022","unstructured":"Zou Y, et al. Blood-brain barrier\u2013penetrating single CRISPR\/Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci Adv. 2022. https:\/\/doi.org\/10.1126\/SCIADV.ABM8011.","journal-title":"Sci Adv"},{"key":"2383_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157. https:\/\/doi.org\/10.3389\/fbioe.2023.1143157.","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"2383_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102636","volume":"36","author":"N Kalter","year":"2025","unstructured":"Kalter N, et al. Off-target effects in CRISPR-Cas genome editing for human therapeutics: progress and challenges. Mol Ther Nucleic Acids. 2025;36(3):102636. https:\/\/doi.org\/10.1016\/j.omtn.2025.102636.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2383_CR80","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-1-0716-2651-1_26","volume-title":"Retinitis pigmentosa","author":"CL Xu","year":"2023","unstructured":"Xu CL, Ruan MZ, Ragi SD, Tsang SH. \u201cCRISPR off-target analysis platforms.\u201d In: Tsang SH, Quinn PMJ, editors. Retinitis pigmentosa, vol. 560. New York: Springer US; 2023. p. 279\u201385. https:\/\/doi.org\/10.1007\/978-1-0716-2651-1_26."},{"issue":"6","key":"2383_CR81","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1093\/nar\/gkac153","volume":"50","author":"Y Liu","year":"2022","unstructured":"Liu Y, et al. Global chromosome rearrangement induced by CRISPR-Cas9 reshapes the genome and transcriptome of human cells. Nucleic Acids Res. 2022;50(6):3456\u201374. https:\/\/doi.org\/10.1093\/nar\/gkac153.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2383_CR82","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.molcel.2018.06.021","volume":"71","author":"J Shou","year":"2018","unstructured":"Shou J, Li J, Liu Y, Wu Q. Precise and Predictable CRISPR Chromosomal Rearrangements Reveal Principles of Cas9-Mediated Nucleotide Insertion. Mol Cell. 2018;71(4):498\u2013509. https:\/\/doi.org\/10.1016\/j.molcel.2018.06.021.","journal-title":"Mol Cell"},{"key":"2383_CR83","doi-asserted-by":"publisher","first-page":"1138596","DOI":"10.3389\/fbioe.2023.1138596","volume":"11","author":"R Ewaisha","year":"2023","unstructured":"Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeutics\u2014critical considerations for clinical translation. Front Bioeng Biotechnol. 2023;11:1138596. https:\/\/doi.org\/10.3389\/fbioe.2023.1138596.","journal-title":"Front Bioeng Biotechnol"},{"key":"2383_CR84","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/bs.pmbts.2020.12.003","volume":"178","author":"S Roy","year":"2021","unstructured":"Roy S. Immune responses to CRISPR-Cas protein. Progr Mol Biol Transl Sci. 2021;178:213\u201329. https:\/\/doi.org\/10.1016\/bs.pmbts.2020.12.003.","journal-title":"Progr Mol Biol Transl Sci"},{"issue":"1","key":"2383_CR85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","volume":"109","author":"A Mehta","year":"2020","unstructured":"Mehta A, Merkel OM. Immunogenicity of Cas9 Protein. J Pharm Sci. 2020;109(1):62\u20137. https:\/\/doi.org\/10.1016\/j.xphs.2019.10.003.","journal-title":"J Pharm Sci"},{"issue":"3","key":"2383_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102634","volume":"36","author":"S-J Park","year":"2025","unstructured":"Park S-J, Lee GE, Cho SM, Choi E-H. Recent applications, future perspectives, and limitations of the CRISPR-Cas system. Mol Ther Nucleic Acids. 2025;36(3):102634. https:\/\/doi.org\/10.1016\/j.omtn.2025.102634.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"2383_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62606-z","volume":"16","author":"C Aussel","year":"2025","unstructured":"Aussel C, Cathomen T, Fuster-Garc\u00eda C. The hidden risks of CRISPR\/Cas: structural variations and genome integrity. Nat Commun. 2025;16(1):7208. https:\/\/doi.org\/10.1038\/s41467-025-62606-z.","journal-title":"Nat Commun"},{"issue":"1","key":"2383_CR88","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0044-1785234","volume":"11","author":"ND Kolanu","year":"2024","unstructured":"Kolanu ND. CRISPR\u2013Cas9 gene editing: curing genetic diseases by inherited epigenetic modifications. Glob Med Genet. 2024;11(1):113\u201322. https:\/\/doi.org\/10.1055\/s-0044-1785234.","journal-title":"Glob Med Genet"},{"issue":"3","key":"2383_CR89","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/ijms23031832","volume":"23","author":"E Erkut","year":"2022","unstructured":"Erkut E, Yokota T. CRISPR therapeutics for duchenne muscular dystrophy. IJMS. 2022;23(3):1832. https:\/\/doi.org\/10.3390\/ijms23031832.","journal-title":"IJMS"},{"issue":"4","key":"2383_CR90","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/crispr.2020.0025","volume":"3","author":"LS Tay","year":"2020","unstructured":"Tay LS, Palmer N, Panwala R, Chew WL, Mali P. Translating CRISPR-Cas therapeutics: approaches and challenges. CRISPR J. 2020;3(4):253\u201375. https:\/\/doi.org\/10.1089\/crispr.2020.0025.","journal-title":"CRISPR J"},{"key":"2383_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2022.111274","volume":"334","author":"TUG Mir","year":"2022","unstructured":"Mir TUG, Wani AK, Akhtar N, Shukla S. CRISPR\/Cas9: regulations and challenges for law enforcement to combat its dual-use. Forensic Sci Int. 2022;334:111274. https:\/\/doi.org\/10.1016\/j.forsciint.2022.111274.","journal-title":"Forensic Sci Int"},{"issue":"1","key":"2383_CR92","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","volume":"431","author":"C Brokowski","year":"2019","unstructured":"Brokowski C, Adli M. CRISPR ethics: moral considerations for applications of a powerful tool. J Mol Biol. 2019;431(1):88\u2013101. https:\/\/doi.org\/10.1016\/j.jmb.2018.05.044.","journal-title":"J Mol Biol"},{"key":"2383_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1737468","volume":"16","author":"RK Yashooa","year":"2026","unstructured":"Yashooa RK, et al. CRISPR\u2013Cas technologies in neurodegenerative disorders: mechanistic insights, therapeutic potential, and translational challenges. Front Neurol. 2026;16:1737468. https:\/\/doi.org\/10.3389\/fneur.2025.1737468.","journal-title":"Front Neurol"},{"key":"2383_CR94","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/J.SAJB.2023.06.009","volume":"159","author":"MF Seleiman","year":"2023","unstructured":"Seleiman MF, Ahmad A, Battaglia ML, Bilal HM, Alhammad BA, Khan N. Zinc oxide nanoparticles: a unique saline stress mitigator with the potential to increase future crop production. S Afr J Bot. 2023;159:208\u201318. https:\/\/doi.org\/10.1016\/J.SAJB.2023.06.009.","journal-title":"S Afr J Bot"},{"issue":"2","key":"2383_CR95","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4155\/TDE.11.156","volume":"3","author":"Y Liu","year":"2012","unstructured":"Liu Y, Tan J, Thomas A, Ou-Yang D, Muzykantov VR. The shape of things to come: importance of design in nanotechnology for drug delivery. Ther Deliv. 2012;3(2):181\u201394. https:\/\/doi.org\/10.4155\/TDE.11.156.","journal-title":"Ther Deliv"},{"issue":"1","key":"2383_CR96","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1021\/NN900002M","volume":"3","author":"OC Farokhzad","year":"2009","unstructured":"Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16\u201320. https:\/\/doi.org\/10.1021\/NN900002M.","journal-title":"ACS Nano"},{"issue":"9","key":"2383_CR97","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3390\/PHARMACEUTICS14091965","volume":"14","author":"S Bozzer","year":"2022","unstructured":"Bozzer S, Dal Bo M, Grimaldi MC, Toffoli G, Macor P. Nanocarriers as a delivery platform for anticancer treatment: biological limits and perspectives in B-Cell malignancies. Pharm. 2022;14(9):1965. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14091965.","journal-title":"Pharm"},{"issue":"5","key":"2383_CR98","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1734-1140(12)70901-5","volume":"64","author":"AZ Wilczewska","year":"2012","unstructured":"Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020\u201337. https:\/\/doi.org\/10.1016\/S1734-1140(12)70901-5.","journal-title":"Pharmacol Rep"},{"key":"2383_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/FCHEM.2022.957572","volume":"10","author":"F Hejabi","year":"2022","unstructured":"Hejabi F, Abbaszadeh MS, Taji S, O\u2019Neill A, Farjadian F, Doroudian M. Nanocarriers: a novel strategy for the delivery of CRISPR\/Cas systems. Front Chem. 2022;10:957572. https:\/\/doi.org\/10.3389\/FCHEM.2022.957572.","journal-title":"Front Chem"},{"issue":"4","key":"2383_CR100","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2174\/1568009623666230803111718","volume":"24","author":"NS Dhote","year":"2024","unstructured":"Dhote NS, Patel RD, Kuwar U, Agrawal M, Alexander A, Jain P. Application of thermoresponsive smart polymers based in situ gel as a novel carrier for tumor targeting. Curr Cancer Drug Targets. 2024;24(4):375\u201396. https:\/\/doi.org\/10.2174\/1568009623666230803111718.","journal-title":"Curr Cancer Drug Targets"},{"key":"2383_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/FCHEM.2021.580118","author":"N Dhiman","year":"2021","unstructured":"Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021. https:\/\/doi.org\/10.3389\/FCHEM.2021.580118.","journal-title":"Front Chem"},{"key":"2383_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS14122682","author":"L Yang","year":"2022","unstructured":"Yang L, et al. Recent advances in lipid nanoparticles for delivery of mRNA. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14122682.","journal-title":"Pharmaceutics"},{"key":"2383_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24606","author":"A Mohammadian Farsani","year":"2024","unstructured":"Mohammadian Farsani A, et al. Lipid nanoparticles: the game-changer in CRISPR\/Cas9 genome-editing. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24606.","journal-title":"Heliyon"},{"issue":"17","key":"2383_CR104","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.7150\/THNO.77259","volume":"12","author":"HN Jung","year":"2022","unstructured":"Jung HN, Lee SY, Lee S, Youn H, Im HJ. Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging. Theranostics. 2022;12(17):7509\u201331. https:\/\/doi.org\/10.7150\/THNO.77259.","journal-title":"Theranostics"},{"key":"2383_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS15020597","author":"M Berger","year":"2023","unstructured":"Berger M, et al. Effect of PEG anchor and serum on lipid nanoparticles: development of a nanoparticles tracking method. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15020597.","journal-title":"Pharmaceutics"},{"issue":"12","key":"2383_CR106","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2217\/NNM-2020-0412","volume":"16","author":"H Akbaba","year":"2021","unstructured":"Akbaba H, Erel-Akbaba G, Senturk S. Special focus issue part II: recruitment of solid lipid nanoparticles for the delivery of CRISPR\/Cas9: primary evaluation of anticancer gene editing. Nanomedicine. 2021;16(12):963\u201378. https:\/\/doi.org\/10.2217\/NNM-2020-0412.","journal-title":"Nanomedicine"},{"key":"2383_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS13070568","author":"S Wang","year":"2024","unstructured":"Wang S, Zhu Y, Du S, Zheng Y. Preclinical advances in LNP-CRISPR therapeutics for solid tumor treatment. Cells. 2024. https:\/\/doi.org\/10.3390\/CELLS13070568.","journal-title":"Cells"},{"issue":"6","key":"2383_CR108","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/ACS.MOLPHARMACEUT.1C00916","volume":"19","author":"P Kazemian","year":"2022","unstructured":"Kazemian P, Yu SY, Thomson SB, Birkenshaw A, Leavitt BR, Ross CJD. Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components. Mol Pharm. 2022;19(6):1669\u201386. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.1C00916.","journal-title":"Mol Pharm"},{"key":"2383_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/J.SUPFLU.2020.104984","volume":"165","author":"L Maja","year":"2020","unstructured":"Maja L, \u017deljko K, Mateja P. Sustainable technologies for liposome preparation. J Supercrit Fluids. 2020;165:104984. https:\/\/doi.org\/10.1016\/J.SUPFLU.2020.104984.","journal-title":"J Supercrit Fluids"},{"key":"2383_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS8030025","author":"SGM Ong","year":"2016","unstructured":"Ong SGM, Ming LC, Lee KS, Yuen KH. Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Pharmaceutics. 2016. https:\/\/doi.org\/10.3390\/PHARMACEUTICS8030025.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2383_CR111","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/727241","volume":"2011","author":"C Kelly","year":"2011","unstructured":"Kelly C, Jefferies C, Cryan S-A. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011;2011(1):727241. https:\/\/doi.org\/10.1155\/2011\/727241.","journal-title":"J Drug Deliv"},{"key":"2383_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09394","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09394.","journal-title":"Heliyon"},{"key":"2383_CR113","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/J.TIFS.2019.01.013","volume":"85","author":"MRI Shishir","year":"2019","unstructured":"Shishir MRI, Karim N, Gowd V, Zheng X, Chen W. Liposomal delivery of natural product: a promising approach in health research. Trends Food Sci Technol. 2019;85:177\u2013200. https:\/\/doi.org\/10.1016\/J.TIFS.2019.01.013.","journal-title":"Trends Food Sci Technol"},{"key":"2383_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/J.COCIS.2024.101875","volume":"75","author":"R Eugster","year":"2025","unstructured":"Eugster R, Luciani P. Liposomes: bridging the gap from lab to pharmaceuticals. Curr Opin Colloid Interface Sci. 2025;75:101875. https:\/\/doi.org\/10.1016\/J.COCIS.2024.101875.","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"2383_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS14030543","author":"D Lombardo","year":"2022","unstructured":"Lombardo D, Kiselev MA. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14030543.","journal-title":"Pharmaceutics"},{"issue":"8","key":"2383_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/FSN3.70587","volume":"13","author":"MA Rahim","year":"2025","unstructured":"Rahim MA, et al. Liposomal encapsulation in food systems: a review of formulation, processing, and applications. Food Sci Nutr. 2025;13(8):e70587. https:\/\/doi.org\/10.1002\/FSN3.70587.","journal-title":"Food Sci Nutr"},{"issue":"16","key":"2383_CR117","doi-asserted-by":"publisher","first-page":"12844","DOI":"10.3390\/IJMS241612844","volume":"24","author":"X Yin","year":"2023","unstructured":"Yin X, Harmancey R, McPherson DD, Kim H, Huang SL. Liposome-based carriers for CRISPR genome-editing. Int J Mol Sci. 2023;24(16):12844. https:\/\/doi.org\/10.3390\/IJMS241612844.","journal-title":"Int J Mol Sci"},{"key":"2383_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS241713262","author":"P Kawak","year":"2023","unstructured":"Kawak P, Sawaftah NMA, Pitt WG, Husseini GA. Transferrin-Targeted Liposomes in glioblastoma therapy: a review. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/IJMS241713262.","journal-title":"Int J Mol Sci"},{"key":"2383_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS17070885","author":"\u017b Sobol","year":"2025","unstructured":"Sobol \u017b, Chiczewski R, W\u0105tr\u00f3bska-\u015awietlikowska D. Advances in liposomal drug delivery: multidirectional perspectives on overcoming biological barriers. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/PHARMACEUTICS17070885.","journal-title":"Pharmaceutics"},{"key":"2383_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES23092157","author":"J Ahlawat","year":"2018","unstructured":"Ahlawat J, Henriquez G, Narayan M. Enhancing the delivery of chemotherapeutics: role of biodegradable polymeric nanoparticles. Molecules. 2018. https:\/\/doi.org\/10.3390\/MOLECULES23092157.","journal-title":"Molecules"},{"key":"2383_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES25163731","author":"A Zielinska","year":"2020","unstructured":"Zielinska A, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020. https:\/\/doi.org\/10.3390\/MOLECULES25163731.","journal-title":"Molecules"},{"key":"2383_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS16010062","author":"M Lin","year":"2023","unstructured":"Lin M, Wang X. Natural biopolymer-based delivery of CRISPR\/Cas9 for cancer treatment. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/PHARMACEUTICS16010062.","journal-title":"Pharmaceutics"},{"key":"2383_CR123","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/J.SEMCDB.2019.04.007","volume":"96","author":"R Verma","year":"2019","unstructured":"Verma R, Sahu R, Singh DD, Egbo TE. A CRISPR\/Cas9 based polymeric nanoparticles to treat\/inhibit microbial infections. Semin Cell Dev Biol. 2019;96:44\u201352. https:\/\/doi.org\/10.1016\/J.SEMCDB.2019.04.007.","journal-title":"Semin Cell Dev Biol"},{"issue":"3","key":"2383_CR124","doi-asserted-by":"publisher","DOI":"10.5958\/2231-5691.2016.00027.7","volume":"6","author":"SB Gondkar","year":"2016","unstructured":"Gondkar SB, Rasal SP, Saudagar RB. Dendrimer: a review. Asian J Pharm Res. 2016;6(3):186. https:\/\/doi.org\/10.5958\/2231-5691.2016.00027.7.","journal-title":"Asian J Pharm Res"},{"key":"2383_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/POLYM15224369","author":"M P\u00e9rez-Ferreiro","year":"2023","unstructured":"P\u00e9rez-Ferreiro M, Abelairas AM, Criado A, G\u00f3mez IJ, Mosquera J. Dendrimers: exploring their wide structural variety and applications. Polymers. 2023. https:\/\/doi.org\/10.3390\/POLYM15224369.","journal-title":"Polymers"},{"key":"2383_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS17070927","author":"S Alamos-Musre","year":"2025","unstructured":"Alamos-Musre S, et al. From structure to function: the promise of PAMAM dendrimers in biomedical applications. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/PHARMACEUTICS17070927.","journal-title":"Pharmaceutics"},{"key":"2383_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/J.NANTOD.2025.102654","volume":"61","author":"W Liyanage","year":"2025","unstructured":"Liyanage W, Kannan GR, Kannan S, Kannan RM. Efficient intracellular delivery of CRISPR\/Cas9 ribonucleoproteins using dendrimer nanoparticles for robust genomic editing. Nano Today. 2025;61:102654. https:\/\/doi.org\/10.1016\/J.NANTOD.2025.102654.","journal-title":"Nano Today"},{"key":"2383_CR128","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/J.SMAIM.2020.05.002","volume":"1","author":"Z Shi","year":"2020","unstructured":"Shi Z, Zhou Y, Fan T, Lin Y, Zhang H, Mei L. Inorganic nano-carriers based smart drug delivery systems for tumor therapy. Smart Mater Med. 2020;1:32\u201347. https:\/\/doi.org\/10.1016\/J.SMAIM.2020.05.002.","journal-title":"Smart Mater Med"},{"issue":"11","key":"2383_CR129","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/S41551-017-0137-2","volume":"1","author":"K Lee","year":"2017","unstructured":"Lee K, et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng. 2017;1(11):889\u2013901. https:\/\/doi.org\/10.1038\/S41551-017-0137-2.","journal-title":"Nat Biomed Eng"},{"issue":"5","key":"2383_CR130","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/PHARMACEUTICS15051432","volume":"15","author":"NU Khaliq","year":"2023","unstructured":"Khaliq NU, et al. Mesoporous silica nanoparticles as a gene delivery platform for cancer therapy. Pharm. 2023;15(5):1432. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15051432.","journal-title":"Pharm"},{"key":"2383_CR131","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.actbio.2020.07.027","volume":"114","author":"A Noureddine","year":"2020","unstructured":"Noureddine A, et al. Engineering of monosized lipid-coated mesoporous silica nanoparticles for CRISPR delivery. Acta Biomater. 2020;114:358\u201368. https:\/\/doi.org\/10.1016\/j.actbio.2020.07.027.","journal-title":"Acta Biomater"},{"issue":"1","key":"2383_CR132","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/S42823-023-00655-4\/METRICS","volume":"34","author":"M Safarkhani","year":"2024","unstructured":"Safarkhani M, Saeb MR, Lee JH, Huh YS, Rabiee N. Carbon-based nanomaterials for CRISPR\/Cas delivery: a perspective on the design approach. Carbon Lett. 2024;34(1):387\u201397. https:\/\/doi.org\/10.1007\/S42823-023-00655-4\/METRICS.","journal-title":"Carbon Lett"},{"issue":"11","key":"2383_CR133","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1007\/S12033-023-00932-7","volume":"66","author":"C Aslan","year":"2024","unstructured":"Aslan C, Zolbanin NM, Faraji F, Jafari R. Exosomes for CRISPR\/Cas9 delivery: the cutting edge in genome-editing. Mol Biotechnol. 2024;66(11):3092\u2013116. https:\/\/doi.org\/10.1007\/S12033-023-00932-7.","journal-title":"Mol Biotechnol"},{"key":"2383_CR134","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","volume":"266","author":"SM Kim","year":"2017","unstructured":"Kim SM, Yang Y, Oh SJ, Hong Y, Seo M, Jang M. Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting. J Control Release. 2017;266:8\u201316. https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.013.","journal-title":"J Control Release"},{"key":"2383_CR135","doi-asserted-by":"publisher","DOI":"10.26508\/LSA.202000875","author":"KM McAndrews","year":"2021","unstructured":"McAndrews KM, Xiao F, Chronopoulos A, LeBleu VS, Kugeratski FG, Kalluri R. Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer. Life Sci alliance. 2021. https:\/\/doi.org\/10.26508\/LSA.202000875.","journal-title":"Life Sci alliance"},{"key":"2383_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS14102008","author":"MF Mougenot","year":"2022","unstructured":"Mougenot MF, et al. Biomimetic nanovesicles-sources, design, production methods, and applications. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14102008.","journal-title":"Pharmaceutics"},{"key":"2383_CR137","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/J.JCONREL.2024.08.019","volume":"374","author":"K Wu","year":"2024","unstructured":"Wu K, et al. Enhanced delivery of CRISPR\/Cas9 system based on biomimetic nanoparticles for hepatitis B virus therapy. J Control Release. 2024;374:293\u2013311. https:\/\/doi.org\/10.1016\/J.JCONREL.2024.08.019.","journal-title":"J Control Release"},{"issue":"15","key":"2383_CR138","doi-asserted-by":"publisher","first-page":"15025","DOI":"10.1021\/ACSNANO.3C04116","volume":"17","author":"Y Liang","year":"2023","unstructured":"Liang Y, et al. Biomimetic mineralized CRISPR\/Cas RNA nanoparticles for efficient tumor-specific multiplex gene editing. ACS Nano. 2023;17(15):15025\u201343. https:\/\/doi.org\/10.1021\/ACSNANO.3C04116.","journal-title":"ACS Nano"},{"key":"2383_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2021.644319","volume":"3","author":"V Meneghini","year":"2021","unstructured":"Meneghini V, Peviani M, Luciani M, Zambonini G, Gritti A. Delivery platforms for CRISPR\/Cas9 genome editing of glial cells in the central nervous system. Front Genome Ed. 2021;3:644319. https:\/\/doi.org\/10.3389\/fgeed.2021.644319.","journal-title":"Front Genome Ed"},{"key":"2383_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2021.118278","volume":"346","author":"S Khaledian","year":"2022","unstructured":"Khaledian S, Dayani M, Fatahian A, Fatahian R, Martinez F. Efficiency of lipid-based nano drug delivery systems in crossing the blood\u2013brain barrier: a review. J Mol Liq. 2022;346:118278. https:\/\/doi.org\/10.1016\/j.molliq.2021.118278.","journal-title":"J Mol Liq"},{"key":"2383_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2026.156369","volume":"280","author":"HM Almohaimeed","year":"2026","unstructured":"Almohaimeed HM, et al. Exosome precision engineering: a comprehensive method for targeted gene and drug delivery. Pathol Res Pract. 2026;280:156369. https:\/\/doi.org\/10.1016\/j.prp.2026.156369.","journal-title":"Pathol Res Pract"},{"key":"2383_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmcr.2025.100263","volume":"14","author":"TE Petcov","year":"2025","unstructured":"Petcov TE, Silberschmidt VV, Pandele MA, Chiticaru EA, Ioni\u021b\u0103 M, Manole M. Nanostructures: an efficient drug delivery platform for therapy of multiple myeloma. Eur J Med Chem Rep. 2025;14:100263. https:\/\/doi.org\/10.1016\/j.ejmcr.2025.100263.","journal-title":"Eur J Med Chem Rep"},{"key":"2383_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105047","volume":"89","author":"DS Nady","year":"2023","unstructured":"Nady DS, Bakowsky U, Fahmy SA. Recent advances in brain delivery of synthetic and natural nano therapeutics: reviving hope for alzheimer\u2019s disease patients. J Drug Deliv Sci Technol. 2023;89:105047. https:\/\/doi.org\/10.1016\/j.jddst.2023.105047.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"16","key":"2383_CR144","doi-asserted-by":"publisher","first-page":"2409353","DOI":"10.1002\/smll.202409353","volume":"22","author":"EM Clarissa","year":"2026","unstructured":"Clarissa EM, Karmacharya M, Choi H, Kumar S, Cho Y. Nature inspired delivery vehicles for CRISPR-based genome editing. Small. 2026;22(16):2409353. https:\/\/doi.org\/10.1002\/smll.202409353.","journal-title":"Small"},{"issue":"1","key":"2383_CR145","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/pharmaceutics18010011","volume":"18","author":"AB Uzakova","year":"2025","unstructured":"Uzakova AB, Yergaliyeva EM, Yerlanuly A, Mukatayeva ZS. A systematic review of advanced drug delivery systems: engineering strategies, barrier penetration, and clinical progress (2016\u2013April 2025). Pharmaceutics. 2025;18(1):11. https:\/\/doi.org\/10.3390\/pharmaceutics18010011.","journal-title":"Pharmaceutics"},{"key":"2383_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2025.1669104","volume":"13","author":"B Wang","year":"2026","unstructured":"Wang B, Lu J, Zhang X, Hu R, Ma H. Advances in nanomaterial-mediated CRISPR\/Cas delivery: from lipid nanoparticles to vesicle-derived systems. Front Bioeng Biotechnol. 2026;13:1669104. https:\/\/doi.org\/10.3389\/fbioe.2025.1669104.","journal-title":"Front Bioeng Biotechnol"},{"issue":"16","key":"2383_CR147","doi-asserted-by":"publisher","first-page":"12844","DOI":"10.3390\/ijms241612844","volume":"24","author":"X Yin","year":"2023","unstructured":"Yin X, Harmancey R, McPherson DD, Kim H, Huang S-L. Liposome-based carriers for CRISPR genome editing. IJMS. 2023;24(16):12844. https:\/\/doi.org\/10.3390\/ijms241612844.","journal-title":"IJMS"},{"key":"2383_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102728","volume":"65","author":"B Ashok","year":"2021","unstructured":"Ashok B, Peppas NA, Wechsler ME. Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR\/Cas9. J Drug Deliv Sci Technol. 2021;65:102728. https:\/\/doi.org\/10.1016\/j.jddst.2021.102728.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"9","key":"2383_CR149","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1039\/D4CB00116H","volume":"5","author":"S Zamolo","year":"2024","unstructured":"Zamolo S, Zakharova E, Boursinhac L, Hollfelder F, Darbre T, Reymond J-L. Peptide dendrimers transfecting CRISPR\/Cas9 plasmid DNA: optimization and mechanism. RSC Chem Biol. 2024;5(9):891\u2013900. https:\/\/doi.org\/10.1039\/D4CB00116H.","journal-title":"RSC Chem Biol"},{"issue":"7","key":"2383_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071495","volume":"14","author":"A Garc\u00eda-Fern\u00e1ndez","year":"2022","unstructured":"Garc\u00eda-Fern\u00e1ndez A, et al. Nanodevices for the efficient codelivery of CRISPR-Cas9 editing machinery and an entrapped cargo: a proposal for dual anti-inflammatory therapy. Pharmaceutics. 2022;14(7):1495. https:\/\/doi.org\/10.3390\/pharmaceutics14071495.","journal-title":"Pharmaceutics"},{"issue":"11","key":"2383_CR151","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1007\/s12033-023-00932-7","volume":"66","author":"C Aslan","year":"2024","unstructured":"Aslan C, Zolbanin NM, Faraji F, Jafari R. Exosomes for CRISPR-Cas9 delivery: the cutting edge in genome editing. Mol Biotechnol. 2024;66(11):3092\u2013116. https:\/\/doi.org\/10.1007\/s12033-023-00932-7.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"2383_CR152","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1186\/s12951-024-03065-4","volume":"22","author":"X Jia","year":"2024","unstructured":"Jia X, et al. Gene editing tool-loaded biomimetic cationic vesicles with highly efficient bacterial internalization for in vivo eradication of pathogens. J Nanobiotechnol. 2024;22(1):787. https:\/\/doi.org\/10.1186\/s12951-024-03065-4.","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"2383_CR153","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.apsb.2024.04.033","volume":"14","author":"B-C Zhang","year":"2024","unstructured":"Zhang B-C, Lai C-M, Luo B-Y, Shao J-W. Triterpenoids-templated self-assembly nanosystem for biomimetic delivery of CRISPR\/Cas9 based on the synergy of TLR-2 and ICB to enhance HCC immunotherapy. Acta Pharmaceutica Sinica B. 2024;14(7):3205\u201317. https:\/\/doi.org\/10.1016\/j.apsb.2024.04.033.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2383_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/NANO12081333","author":"F Ahmad","year":"2022","unstructured":"Ahmad F, et al. Unique properties of surface-functionalized nanoparticles for bio-application: functionalization mechanisms and importance in application. Nanomaterials. 2022. https:\/\/doi.org\/10.3390\/NANO12081333.","journal-title":"Nanomaterials"},{"key":"2383_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/FMOLB.2020.587012","volume":"7","author":"G Sanit\u00e0","year":"2020","unstructured":"Sanit\u00e0 G, Carrese B, Lamberti A. Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization. Front Mol Biosci. 2020;7:587012. https:\/\/doi.org\/10.3389\/FMOLB.2020.587012.","journal-title":"Front Mol Biosci"},{"issue":"17","key":"2383_CR156","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1016\/j.molcel.2021.07.027","volume":"81","author":"KW Barber","year":"2021","unstructured":"Barber KW, Shrock E, Elledge SJ. CRISPR-based peptide library display and programmable microarray self-assembly for rapid quantitative protein binding assays. Mol Cell. 2021;81(17):3650-3658.e5. https:\/\/doi.org\/10.1016\/j.molcel.2021.07.027.","journal-title":"Mol Cell"},{"issue":"2","key":"2383_CR157","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/J.YMGME.2018.12.301","volume":"126","author":"L Pimentel","year":"2019","unstructured":"Pimentel L, et al. Intranasal delivery of the CRISPR\/Cas9 system for gene editing in MPS II mice. Mol Genet Metab. 2019;126(2):S118. https:\/\/doi.org\/10.1016\/J.YMGME.2018.12.301.","journal-title":"Mol Genet Metab"},{"key":"2383_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS17060775","author":"X Wu","year":"2025","unstructured":"Wu X, et al. Intranasal drug delivery technology in the treatment of central nervous system diseases: challenges, advances, and future research directions. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/PHARMACEUTICS17060775.","journal-title":"Pharmaceutics"},{"key":"2383_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS15010207","author":"VA Duong","year":"2023","unstructured":"Duong VA, Nguyen TTL, Maeng HJ. Recent advances in intranasal liposomes for drug, gene, and vaccine delivery. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15010207.","journal-title":"Pharmaceutics"},{"key":"2383_CR160","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/J.ADDR.2020.02.006","volume":"165\u2013166","author":"MJ Fowler","year":"2020","unstructured":"Fowler MJ, Cotter JD, Knight BE, Sevick-Muraca EM, Sandberg DI, Sirianni RW. Intrathecal drug delivery in the era of nanomedicine. Adv Drug Deliv Rev. 2020;165\u2013166:77\u201395. https:\/\/doi.org\/10.1016\/J.ADDR.2020.02.006.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"2383_CR161","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.7150\/THNO.14858","volume":"6","author":"D Liu","year":"2016","unstructured":"Liu D, Yang F, Xiong F, Gu N. The smart drug delivery system and its clinical potential. Theranostics. 2016;6(9):1306\u201323. https:\/\/doi.org\/10.7150\/THNO.14858.","journal-title":"Theranostics"},{"key":"2383_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/FCHEM.2022.1095598","author":"A Rana","year":"2023","unstructured":"Rana A, Adhikary M, Singh PK, Das BC, Bhatnagar S. \u2018Smart\u2019 drug delivery: a window to future of translational medicine. Front Chem. 2023. https:\/\/doi.org\/10.3389\/FCHEM.2022.1095598.","journal-title":"Front Chem"},{"issue":"6","key":"2383_CR163","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1016\/J.APSB.2022.12.013","volume":"13","author":"C Chen","year":"2023","unstructured":"Chen C, et al. Intelligent nanotherapeutic strategies for the delivery of CRISPR system. Acta Pharm Sin B. 2023;13(6):2510\u201343. https:\/\/doi.org\/10.1016\/J.APSB.2022.12.013.","journal-title":"Acta Pharm Sin B"},{"key":"2383_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/S12951-025-03247-8","author":"J Liu","year":"2025","unstructured":"Liu J, Wang T, Dong J, Lu Y. The blood-brain barriers: novel nanocarriers for central nervous system diseases. J Nanobiotechnology. 2025. https:\/\/doi.org\/10.1186\/S12951-025-03247-8.","journal-title":"J Nanobiotechnology"},{"issue":"10","key":"2383_CR165","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.7150\/THNO.38069","volume":"10","author":"P Mi","year":"2020","unstructured":"Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10(10):4557\u201388. https:\/\/doi.org\/10.7150\/THNO.38069.","journal-title":"Theranostics"},{"issue":"9","key":"2383_CR166","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/J.ADDR.2012.01.020","volume":"64","author":"E Fleige","year":"2012","unstructured":"Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev. 2012;64(9):866\u201384. https:\/\/doi.org\/10.1016\/J.ADDR.2012.01.020.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2383_CR167","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1573413711666150706183157","volume":"12","author":"F Liu","year":"2015","unstructured":"Liu F, et al. Stimuli-responsive nanocarriers for drug delivery to the central nervous system. Curr Nanosci. 2015;12(1):4\u201317. https:\/\/doi.org\/10.2174\/1573413711666150706183157.","journal-title":"Curr Nanosci"},{"issue":"2","key":"2383_CR168","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","volume":"18","author":"J Majumder","year":"2021","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18(2):205\u201327. https:\/\/doi.org\/10.1080\/17425247.2021.1828339.","journal-title":"Expert Opin Drug Deliv"},{"key":"2383_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/MA14227010","author":"X Liu","year":"2021","unstructured":"Liu X, Zhou H, Yu W, Xiong X, Krastev R, Ma X. Preparation of cationic amphiphilic nanoparticles with modified chitosan derivatives for doxorubicin delivery. Materials. 2021. https:\/\/doi.org\/10.3390\/MA14227010.","journal-title":"Materials"},{"key":"2383_CR170","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-84860-6_177","author":"G Onzi","year":"2022","unstructured":"Onzi G, Guterres SS, Pohlmann AR, Frank LA. Stimuli-responsive nanocarriers for drug delivery. ADME Encycl. 2022. https:\/\/doi.org\/10.1007\/978-3-030-84860-6_177.","journal-title":"ADME Encycl"},{"issue":"12","key":"2383_CR171","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s11064-009-0081-y","volume":"34","author":"J Correale","year":"2009","unstructured":"Correale J, Villa A. Cellular elements of the blood-brain barrier. Neurochem Res. 2009;34(12):2067\u201377. https:\/\/doi.org\/10.1007\/s11064-009-0081-y.","journal-title":"Neurochem Res"},{"issue":"3","key":"2383_CR172","doi-asserted-by":"publisher","first-page":"C343","DOI":"10.1152\/AJPCELL.00095.2018","volume":"315","author":"W Abdullahi","year":"2018","unstructured":"Abdullahi W, Tripathi D, Ronaldson PT. Blood-brain barrier dysfunction in ischemic stroke: targeting tight junctions and transporters for vascular protection. Am J Physiol Cell Physiol. 2018;315(3):C343\u201356. https:\/\/doi.org\/10.1152\/AJPCELL.00095.2018.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"2383_CR173","first-page":"62","volume":"2","author":"A Sehgal","year":"2025","unstructured":"Sehgal A, Kumar P, Singh A. Mitochondrial crosstalk in neurodegeneration: mechanistic pathways, quality control, and therapeutic perspectives. Probecell Sci. 2025;2(2):62\u201378.","journal-title":"Probecell Sci"},{"key":"2383_CR174","doi-asserted-by":"publisher","DOI":"10.3389\/FMEDT.2020.623950","author":"A Williams-Medina","year":"2021","unstructured":"Williams-Medina A, Deblock M, Janigro D. In vitro models of the blood-brain barrier: tools in translational medicine. Front Med Technol. 2021. https:\/\/doi.org\/10.3389\/FMEDT.2020.623950.","journal-title":"Front Med Technol"},{"key":"2383_CR175","doi-asserted-by":"publisher","DOI":"10.1002\/ADVS.202205752","author":"W Wei","year":"2023","unstructured":"Wei W, Cardes F, Hierlemann A, Modena MM. 3D in vitro blood\u2013brain barrier model for investigating barrier insults. Adv Sci. 2023. https:\/\/doi.org\/10.1002\/ADVS.202205752.","journal-title":"Adv Sci"},{"key":"2383_CR176","doi-asserted-by":"publisher","DOI":"10.1111\/CTS.13695","author":"L Wang","year":"2023","unstructured":"Wang L, Hu D, Xu J, Hu J, Wang Y. Complex in vitro model: a transformative model in drug development and precision medicine. Clin Transl Sci. 2023. https:\/\/doi.org\/10.1111\/CTS.13695.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"2383_CR177","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/PHARMACEUTICS14050993","volume":"14","author":"A Sood","year":"2022","unstructured":"Sood A, Kumar A, Dev A, Gupta VK, Han SS. Advances in hydrogel-based microfluidic blood\u2013brain-barrier models in oncology research. Pharm. 2022;14(5):993. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14050993.","journal-title":"Pharm"},{"issue":"1063\/5","key":"2383_CR178","first-page":"0011583","volume":"10","author":"Q Ramadan","year":"2020","unstructured":"Ramadan Q, Zourob M. Organ-on-a-chip engineering: toward bridging the gap between lab and industry. Biomicrofluidics, DOI. 2020;10(1063\/5):0011583.","journal-title":"Biomicrofluidics, DOI"},{"key":"2383_CR179","doi-asserted-by":"publisher","DOI":"10.3390\/BIOENGINEERING10070817","author":"KNU Galpayage Dona","year":"2023","unstructured":"Galpayage Dona KNU, Ramirez SH, Andrews AM. A next-generation 3D tissue-engineered model of the human brain microvasculature to study the blood-brain barrier. Bioeng. 2023. https:\/\/doi.org\/10.3390\/BIOENGINEERING10070817.","journal-title":"Bioeng"},{"key":"2383_CR180","unstructured":"Dotiwala AK, McCausland C, Samra NS. \u201cAnatomy, head and neck: blood brain barrier\u201d. StatPearls, 2023, Accessed: Sep. 15, 2025. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519556\/"},{"key":"2383_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114816","author":"A P\u00e9rez-L\u00f3pez","year":"2023","unstructured":"P\u00e9rez-L\u00f3pez A, Torres-Su\u00e1rez AI, Mart\u00edn-Sabroso C, Aparicio-Blanco J. An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines. Adv Drug Deliv Rev. 2023. https:\/\/doi.org\/10.1016\/j.addr.2023.114816.","journal-title":"Adv Drug Deliv Rev"},{"key":"2383_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2025.117942","volume":"185","author":"X Liu","year":"2025","unstructured":"Liu X, Zhou Z, Zhang Y, Zhong H, Cai X, Guan R. Recent progress on the organoids: techniques, advantages and applications. Biomed Pharmacother. 2025;185:117942. https:\/\/doi.org\/10.1016\/J.BIOPHA.2025.117942.","journal-title":"Biomed Pharmacother"},{"key":"2383_CR183","doi-asserted-by":"publisher","DOI":"10.3389\/FMOLB.2020.00033","author":"C Jensen","year":"2020","unstructured":"Jensen C, Teng Y. Is it time to start transitioning from 2D to 3D cell culture? Front Mol Biosci. 2020. https:\/\/doi.org\/10.3389\/FMOLB.2020.00033.","journal-title":"Front Mol Biosci"},{"issue":"10","key":"2383_CR184","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1091\/MBC.E19-03-0135","volume":"30","author":"R Lehmann","year":"2019","unstructured":"Lehmann R, et al. Human organoids: a new dimension in cell biology. Mol Biol Cell. 2019;30(10):1129\u201337. https:\/\/doi.org\/10.1091\/MBC.E19-03-0135.","journal-title":"Mol Biol Cell"},{"issue":"29","key":"2383_CR185","doi-asserted-by":"publisher","first-page":"16044","DOI":"10.1002\/ANIE.202103557","volume":"60","author":"P Su","year":"2021","unstructured":"Su P, et al. Exceptional electrochemical HER performance with enhanced electron transfer between Ru nanoparticles and single atoms dispersed on a carbon substrate. Angew Chem Int Ed Engl. 2021;60(29):16044\u201350. https:\/\/doi.org\/10.1002\/ANIE.202103557.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"2383_CR186","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/S41580-024-00804-1SUBJMETA","volume":"26","author":"M Birtele","year":"2025","unstructured":"Birtele M, Lancaster M, Quadrato G. Modelling human brain development and disease with organoids. Nat Rev Mol Cell Biol. 2025;26(5):389\u2013412. https:\/\/doi.org\/10.1038\/S41580-024-00804-1SUBJMETA.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2383_CR187","doi-asserted-by":"publisher","first-page":"C151","DOI":"10.1152\/AJPCELL.00120.2020","volume":"319","author":"C Corr\u00f2","year":"2020","unstructured":"Corr\u00f2 C, Novellasdemunt L, Li VSW. A brief history of organoids. Am J Physiol Cell Physiol. 2020;319(1):C151\u201365. https:\/\/doi.org\/10.1152\/AJPCELL.00120.2020.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"11","key":"2383_CR188","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/S41684-024-01458-4","volume":"53","author":"MCJ Chang","year":"2024","unstructured":"Chang MCJ, Grieder FB. The continued importance of animals in biomedical research. Lab Anim. 2024;53(11):295. https:\/\/doi.org\/10.1038\/S41684-024-01458-4.","journal-title":"Lab Anim"},{"issue":"1","key":"2383_CR189","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9978571","volume":"2022","author":"Y Zhu","year":"2022","unstructured":"Zhu Y. Advances in CRISPR\/Cas9. BioMed Res Int. 2022;2022(1):9978571. https:\/\/doi.org\/10.1155\/2022\/9978571.","journal-title":"BioMed Res Int"},{"key":"2383_CR190","doi-asserted-by":"publisher","DOI":"10.1159\/000547334","author":"MA Karimi","year":"2025","unstructured":"Karimi MA, Paryan M, Fard GB, Sadeghian H, Zarrinfar H, Bafghi MH. Challenges and opportunities in the application of CRISPR\/Cas9: a review on genomic editing and therapeutic potentials. Med Princ Pract. 2025. https:\/\/doi.org\/10.1159\/000547334.","journal-title":"Med Princ Pract"},{"key":"2383_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2022.947769\/FULL","volume":"10","author":"CP Barrag\u00e1n-\u00c1lvarez","year":"2022","unstructured":"Barrag\u00e1n-\u00c1lvarez CP, et al. Recent advances in the use of CRISPR\/Cas for understanding the early development of molecular gaps in glial cells. Front Cell Dev Biol. 2022;10:947769. https:\/\/doi.org\/10.3389\/FCELL.2022.947769\/FULL.","journal-title":"Front Cell Dev Biol"},{"key":"2383_CR192","doi-asserted-by":"publisher","DOI":"10.3389\/FNCEL.2025.1578138","author":"MS Khan","year":"2025","unstructured":"Khan MS, Qureshi N, Khan R, Son YO, Maqbool T. CRISPR\/Cas9-based therapeutics as a promising strategy for management of Alzheimer\u2019s disease: progress and prospects. Front Cell Neurosci. 2025. https:\/\/doi.org\/10.3389\/FNCEL.2025.1578138.","journal-title":"Front Cell Neurosci"},{"issue":"14","key":"2383_CR193","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3969\/J.ISSN.1673-5374.2013.14.006","volume":"8","author":"M He","year":"2013","unstructured":"He M, Liu J, Cheng S, Xing Y, Suo WZ. Differentiation renders susceptibility to excitotoxicity in HT22 neurons. Neural Regen Res. 2013;8(14):1297\u2013306. https:\/\/doi.org\/10.3969\/J.ISSN.1673-5374.2013.14.006.","journal-title":"Neural Regen Res"},{"key":"2383_CR194","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-115","author":"B Stansley","year":"2012","unstructured":"Stansley B, Post J, Hensley K. A comparative review of cell culture systems for the study of microglial biology in alzheimer\u2019s disease. J Neuroinflammation. 2012. https:\/\/doi.org\/10.1186\/1742-2094-9-115.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"2383_CR195","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/19768354.2020.1726462","volume":"24","author":"H Lee","year":"2020","unstructured":"Lee H, Yoon DE, Kim K. genome-editing methods in animal models. Animal Cells Syst. 2020;24(1):8\u201316. https:\/\/doi.org\/10.1080\/19768354.2020.1726462.","journal-title":"Animal Cells Syst"},{"key":"2383_CR196","doi-asserted-by":"publisher","DOI":"10.1111\/ACEL.13347","author":"M Niu","year":"2021","unstructured":"Niu M, et al. VPS35 D620N knockin mice recapitulate cardinal features of Parkinson\u2019s disease. Aging Cell. 2021. https:\/\/doi.org\/10.1111\/ACEL.13347.","journal-title":"Aging Cell"},{"key":"2383_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-018-30436-3","author":"XX Zhu","year":"2018","unstructured":"Zhu XX, Zhong YZ, Ge YW, Lu KH, Lu SS. CRISPR\/Cas9-mediated generation of Guangxi Bama Minipigs harboring three mutations in \u03b1-synuclein causing parkinson\u2019s disease. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/S41598-018-30436-3.","journal-title":"Sci Rep"},{"issue":"4","key":"2383_CR198","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cell.2018.03.005","volume":"173","author":"S Yan","year":"2018","unstructured":"Yan S, et al. A Huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington\u2019s disease. Cell. 2018;173(4):989-1002.e13. https:\/\/doi.org\/10.1016\/j.cell.2018.03.005.","journal-title":"Cell"},{"issue":"9","key":"2383_CR199","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/17425247.2018.1517746","volume":"15","author":"DC Luther","year":"2018","unstructured":"Luther DC, Lee YW, Nagaraj H, Scaletti F, Rotello VM. Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: advances and challenges. Expert Opin Drug Deliv. 2018;15(9):905\u201313. https:\/\/doi.org\/10.1080\/17425247.2018.1517746.","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"2383_CR200","doi-asserted-by":"publisher","DOI":"10.3390\/genes16080850","volume":"16","author":"A Akbar","year":"2025","unstructured":"Akbar A, et al. CRISPR in neurodegenerative diseases treatment: an alternative approach to current therapies. Genes. 2025;16(8):850. https:\/\/doi.org\/10.3390\/genes16080850.","journal-title":"Genes"},{"key":"2383_CR201","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jconrel.2022.09.046","volume":"351","author":"W Ruan","year":"2022","unstructured":"Ruan W, et al. Brain-targeted CRISPR\/Cas9 nanomedicine for effective glioblastoma therapy. J Control Release. 2022;351:739\u201351. https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.046.","journal-title":"J Control Release"},{"issue":"3","key":"2383_CR202","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10565-019-09475-7","volume":"35","author":"DC Wang","year":"2019","unstructured":"Wang DC, Wang X. Off-target genome editing: a new discipline of gene science and a new class of medicine. Cell Biol Toxicol. 2019;35(3):179\u201383. https:\/\/doi.org\/10.1007\/s10565-019-09475-7.","journal-title":"Cell Biol Toxicol"},{"issue":"1","key":"2383_CR203","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","volume":"10","author":"G Cullot","year":"2019","unstructured":"Cullot G, et al. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. Nat Commun. 2019;10(1):1136. https:\/\/doi.org\/10.1038\/s41467-019-09006-2.","journal-title":"Nat Commun"},{"issue":"21","key":"2383_CR204","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","volume":"186","author":"CA Tsuchida","year":"2023","unstructured":"Tsuchida CA, et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell. 2023;186(21):4567-4582.e20. https:\/\/doi.org\/10.1016\/j.cell.2023.08.041.","journal-title":"Cell"},{"issue":"12","key":"2383_CR205","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14737159.2025.2581677","volume":"25","author":"M Lotfi","year":"2025","unstructured":"Lotfi M, Farshchian Yazdi Z, Hashemi MR, Abbaszadegan MR, Sharif S. Guarding the genome: strategies for off-target detection and minimization in CRISPR\/Cas9 system. Expert Rev Mol Diagn. 2025;25(12):883\u2013902. https:\/\/doi.org\/10.1080\/14737159.2025.2581677.","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"2383_CR206","doi-asserted-by":"publisher","first-page":"439","DOI":"10.32604\/or.2023.044473","volume":"32","author":"E Amjad","year":"2024","unstructured":"Amjad E, Pezzani R, Sokouti B. A review of the literature on the use of CRISPR\/Cas9 gene therapy to treat hepatocellular carcinoma. OR. 2024;32(3):439\u201361. https:\/\/doi.org\/10.32604\/or.2023.044473.","journal-title":"OR"},{"key":"2383_CR207","doi-asserted-by":"publisher","first-page":"1724291","DOI":"10.3389\/fgeed.2025.1724291","volume":"7","author":"A Bharti","year":"2025","unstructured":"Bharti A, Mudge J. Therapeutic applications of CRISPR-Cas9 gene editing. Front Genome Ed. 2025;7:1724291. https:\/\/doi.org\/10.3389\/fgeed.2025.1724291.","journal-title":"Front Genome Ed"},{"issue":"1","key":"2383_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2026.102859","volume":"37","author":"C Chakraborty","year":"2026","unstructured":"Chakraborty C, Bhattacharya M, Das A, Agoramoorthy G, Lee S-S. CRISPR-Cas9-mediated therapeutics: current clinical trials and therapy approval landscape to treat human diseases. Mol Ther Nucleic Acids. 2026;37(1):102859. https:\/\/doi.org\/10.1016\/j.omtn.2026.102859.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2383_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.973326","volume":"10","author":"RA Foley","year":"2022","unstructured":"Foley RA, Sims RA, Duggan EC, Olmedo JK, Ma R, Jonas SJ. Delivering the CRISPR\/Cas9 system for engineering gene therapies: recent cargo and delivery approaches for clinical translation. Front Bioeng Biotechnol. 2022;10:973326. https:\/\/doi.org\/10.3389\/fbioe.2022.973326.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"2383_CR210","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bj.2019.10.005","volume":"43","author":"B Paul","year":"2020","unstructured":"Paul B, Montoya G. CRISPR-Cas12a: functional overview and applications. Biomed J. 2020;43(1):8\u201317. https:\/\/doi.org\/10.1016\/j.bj.2019.10.005.","journal-title":"Biomed J"},{"issue":"1","key":"2383_CR211","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/NBT.3737","volume":"35","author":"B Zetsche","year":"2017","unstructured":"Zetsche B, et al. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array. Nat Biotechnol. 2017;35(1):31\u20134. https:\/\/doi.org\/10.1038\/NBT.3737.","journal-title":"Nat Biotechnol"},{"key":"2383_CR212","doi-asserted-by":"publisher","DOI":"10.1186\/S12915-022-01296-1","author":"H Huang","year":"2022","unstructured":"Huang H, et al. Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity. BMC Biol. 2022. https:\/\/doi.org\/10.1186\/S12915-022-01296-1.","journal-title":"BMC Biol"},{"issue":"8","key":"2383_CR213","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/S41580-019-0131-5","volume":"20","author":"A Pickar-Oliver","year":"2019","unstructured":"Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490\u2013507. https:\/\/doi.org\/10.1038\/S41580-019-0131-5.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2383_CR214","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/J.JMB.2018.06.029","volume":"431","author":"MR O\u2019Connell","year":"2019","unstructured":"O\u2019Connell MR. Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPR-Cas systems. J Mol Biol. 2019;431(1):66\u201387. https:\/\/doi.org\/10.1016\/J.JMB.2018.06.029.","journal-title":"J Mol Biol"},{"key":"2383_CR215","doi-asserted-by":"publisher","DOI":"10.34133\/BDR.0041","author":"G Zhu","year":"2024","unstructured":"Zhu G, Zhou X, Wen M, Qiao J, Li G, Yao Y. CRISPR\u2013Cas13: pioneering RNA editing for nucleic acid therapeutics. BioDesign Res. 2024. https:\/\/doi.org\/10.34133\/BDR.0041.","journal-title":"BioDesign Res"},{"issue":"7","key":"2383_CR216","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.tibtech.2020.10.010","volume":"39","author":"MA Zeballos","year":"2021","unstructured":"Zeballos MA, Gaj T. Next-generation CRISPR technologies and their applications in gene and cell therapy. Trends Biotechnol. 2021;39(7):692\u2013705. https:\/\/doi.org\/10.1016\/j.tibtech.2020.10.010.","journal-title":"Trends Biotechnol"},{"issue":"9","key":"2383_CR217","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.ymthe.2020.07.021","volume":"28","author":"YK Jeong","year":"2020","unstructured":"Jeong YK, Song B, Bae S. Current status and challenges of DNA base editing tools. Mol Ther. 2020;28(9):1938\u201352. https:\/\/doi.org\/10.1016\/j.ymthe.2020.07.021.","journal-title":"Mol Ther"},{"issue":"17","key":"2383_CR218","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21176240","volume":"21","author":"A Kantor","year":"2020","unstructured":"Kantor A, McClements ME, Maclaren RE. CRISPR\/Cas9 DNA base-editing and prime-editing. Int J Mol Sci. 2020;21(17):1\u201322. https:\/\/doi.org\/10.3390\/IJMS21176240.","journal-title":"Int J Mol Sci"},{"key":"2383_CR219","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKAE1217","author":"JM Lee","year":"2025","unstructured":"Lee JM, et al. Direct delivery of Cas-embedded cytosine base editors as ribonucleoprotein complexes for efficient and accurate editing of clinically relevant targets. Nucleic Acids Res. 2025. https:\/\/doi.org\/10.1093\/NAR\/GKAE1217.","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"2383_CR220","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199409","volume":"26","author":"M \u0218erban","year":"2025","unstructured":"\u0218erban M, Toader C, Covache-Busuioc R-A. CRISPR and artificial intelligence in neuroregeneration: closed-loop strategies for precision medicine, spinal cord repair, and adaptive neuro-oncology. Int J Mol Sci. 2025;26(19):9409. https:\/\/doi.org\/10.3390\/ijms26199409.","journal-title":"Int J Mol Sci"},{"key":"2383_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/J.COMPBIOMED.2024.109137","volume":"182","author":"A Boretti","year":"2024","unstructured":"Boretti A. The transformative potential of AI-driven CRISPR\/Cas9 genome-editing to enhance CAR T-cell therapy. Comput Biol Med. 2024;182:109137. https:\/\/doi.org\/10.1016\/J.COMPBIOMED.2024.109137.","journal-title":"Comput Biol Med"},{"key":"2383_CR222","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1462697","author":"M Amiri","year":"2024","unstructured":"Amiri M, Moaveni AK, Majidi Zolbin M, Shademan B, Nourazarian A. Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR\/Cas9. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/FIMMU.2024.1462697.","journal-title":"Front Immunol"},{"key":"2383_CR223","doi-asserted-by":"publisher","DOI":"10.1016\/j.humgen.2024.201297","volume":"41","author":"M Dara","year":"2024","unstructured":"Dara M, Dianatpour M, Azarpira N, Omidifar N. Convergence of CRISPR and artificial intelligence: a paradigm shift in biotechnology. Hum Gene Ther. 2024;41:201297. https:\/\/doi.org\/10.1016\/j.humgen.2024.201297.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"2383_CR224","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/S12276-025-01462-9;SUBJMETA","volume":"57","author":"MG Kim","year":"2025","unstructured":"Kim MG, Go MJ, Kang SH, Jeong SH, Lim K. Revolutionizing CRISPR technology with artificial intelligence. Exp Mol Med. 2025;57(7):1419\u201331. https:\/\/doi.org\/10.1038\/S12276-025-01462-9;SUBJMETA.","journal-title":"Exp Mol Med"},{"key":"2383_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2026.110695","volume":"429","author":"S Kumar","year":"2026","unstructured":"Kumar S, Malviya R, Sridhar SB, Wadhwa T, Shareef J. Artificial intelligence and machine learning driven nanorobotics for targeted brain delivery: redefining blood-brain barrier navigation. J Neurosci Methods. 2026;429:110695. https:\/\/doi.org\/10.1016\/j.jneumeth.2026.110695.","journal-title":"J Neurosci Methods"},{"key":"2383_CR226","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1354825","author":"R Tao","year":"2024","unstructured":"Tao R, et al. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/FIMMU.2024.1354825.","journal-title":"Front Immunol"},{"issue":"1","key":"2383_CR227","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40364-024-00602-Z\/TABLES\/3","volume":"12","author":"P Song","year":"2024","unstructured":"Song P, Zhang Q, Xu Z, Shi Y, Jing R, Luo D. CRISPR\/Cas-based CAR-T cells: production and application. Biomark Res. 2024;12(1):1\u201312. https:\/\/doi.org\/10.1186\/S40364-024-00602-Z\/TABLES\/3.","journal-title":"Biomark Res"},{"issue":"1","key":"2383_CR228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-025-03112-8\/FIGURES\/7","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu X, et al. Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade. J Nanobiotechnology. 2025;23(1):1\u201318. https:\/\/doi.org\/10.1186\/S12951-025-03112-8\/FIGURES\/7.","journal-title":"J Nanobiotechnology"},{"key":"2383_CR229","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-025-59377-Y","author":"X Liang","year":"2025","unstructured":"Liang X, et al. Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/S41467-025-59377-Y.","journal-title":"Nat Commun"},{"issue":"4","key":"2383_CR230","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/J.RMR.2023.01.026","volume":"40","author":"M Georget","year":"2023","unstructured":"Georget M, Pisan E. Approches diagnostiques bas\u00e9es sur le s\u00e9quen\u00e7age \u00e0 haut d\u00e9bit. Rev Mal Respir. 2023;40(4):345\u201358. https:\/\/doi.org\/10.1016\/J.RMR.2023.01.026.","journal-title":"Rev Mal Respir"},{"issue":"3","key":"2383_CR231","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/17410541.2024.2341610","volume":"21","author":"M Mahmood","year":"2024","unstructured":"Mahmood M, Taufiq I, Mazhar S, Hafeez F, Malik K, Afzal S. Revolutionizing personalized cancer treatment: the synergy of next-generation sequencing and CRISPR\/Cas9. Per Med. 2024;21(3):175\u201390. https:\/\/doi.org\/10.1080\/17410541.2024.2341610.","journal-title":"Per Med"},{"key":"2383_CR232","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-021-22932-4","author":"C Hunt","year":"2021","unstructured":"Hunt C, et al. Tissue-specific activation of gene expression by the synergistic activation mediator (SAM) CRISPRa system in mice. Nat Commun. 2021. https:\/\/doi.org\/10.1038\/S41467-021-22932-4.","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"2383_CR233","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/S41434-023-00414-0","volume":"31","author":"LF Narv\u00e1ez-P\u00e9rez","year":"2024","unstructured":"Narv\u00e1ez-P\u00e9rez LF, Paz-Berm\u00fadez F, Avalos-Fuentes JA, Campos-Romo A, Flor\u00e1n-Gardu\u00f1o B, Segovia J. CRISPR\/sgRNA-directed synergistic activation mediator (SAM) as a therapeutic tool for Parkinson\u00b4s disease. Gene Ther. 2024;31(1\u20132):31\u201344. https:\/\/doi.org\/10.1038\/S41434-023-00414-0.","journal-title":"Gene Ther"},{"key":"2383_CR234","doi-asserted-by":"publisher","first-page":"102851","DOI":"10.1016\/j.arr.2025.102851","volume":"111","author":"HK Meshram","year":"2025","unstructured":"Meshram HK, Gupta SK, Gupta A, Nagori K. Next-generation CRISPR gene editing tools in the precision treatment of Alzheimer\u2019s and Parkinson\u2019s disease. Ageing Res Rev. 2025;111:102851. https:\/\/doi.org\/10.1016\/j.arr.2025.102851.","journal-title":"Ageing Res Rev"},{"issue":"2","key":"2383_CR235","first-page":"52","volume":"2","author":"P Kanika","year":"2025","unstructured":"Kanika P, Patel A, Tripathy B. Formulation, characterisation, and evaluation of curcumin nanoparticles in experimental models of alzheimer\u2019s disease. Probecell sci. 2025;2(2):52\u201361.","journal-title":"Probecell sci"},{"issue":"1","key":"2383_CR236","doi-asserted-by":"publisher","first-page":"2516697","DOI":"10.1080\/07853890.2025.2516697","volume":"57","author":"RG Ingle","year":"2025","unstructured":"Ingle RG, Elossaily GM, Ansari MN, Makhijani S. Unlocking the potential: advancements and applications of gene therapy in severe disorders. Ann Med. 2025;57(1):2516697. https:\/\/doi.org\/10.1080\/07853890.2025.2516697.","journal-title":"Ann Med"},{"issue":"1","key":"2383_CR237","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40778-014-0003-z","volume":"1","author":"MH Porteus","year":"2015","unstructured":"Porteus MH. Genome editing of the blood: opportunities and challenges. Curr Stem Cell Rep. 2015;1(1):23\u201330. https:\/\/doi.org\/10.1007\/s40778-014-0003-z.","journal-title":"Curr Stem Cell Rep"},{"key":"2383_CR238","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.foohum.2023.08.023","volume":"1","author":"A Jain","year":"2023","unstructured":"Jain A, Jain P, Bajaj S, Majumdar A, Soni P. Chemoprofiling and antioxidant activity of edible curcuma species. Food Humanit. 2023;1:1027\u201339. https:\/\/doi.org\/10.1016\/j.foohum.2023.08.023.","journal-title":"Food Humanit"},{"issue":"1","key":"2383_CR239","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/MS9.0000000000001500","volume":"86","author":"N Thapar","year":"2024","unstructured":"Thapar N, Eid MAF, Raj N, Kantas T, Billing HS, Sadhu D. Application of CRISPR\/Cas9 in the management of Alzheimer\u2019s disease and Parkinson\u2019s disease: a review. Ann Med Surg. 2024;86(1):329\u201335. https:\/\/doi.org\/10.1097\/MS9.0000000000001500.","journal-title":"Ann Med Surg"},{"issue":"7","key":"2383_CR240","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1021\/acsabm.3c00254","volume":"6","author":"A Vashist","year":"2023","unstructured":"Vashist A, et al. Recent advances in nanotherapeutics for neurological disorders. ACS Appl Bio Mater. 2023;6(7):2614\u201321. https:\/\/doi.org\/10.1021\/acsabm.3c00254.","journal-title":"ACS Appl Bio Mater"},{"issue":"4","key":"2383_CR241","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11481-019-09849-y","volume":"14","author":"SP Raikwar","year":"2019","unstructured":"Raikwar SP, et al. Next generation precision medicine: CRISPR-mediated genome editing for the treatment of neurodegenerative disorders. J Neuroimmune Pharmacol. 2019;14(4):608\u201341. https:\/\/doi.org\/10.1007\/s11481-019-09849-y.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"2383_CR242","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1016\/j.apsb.2025.05.007","volume":"15","author":"Y Xu","year":"2025","unstructured":"Xu Y, Le H, Wu Q, Wang N, Gong C. Advancements in CRISPR\/Cas systems for disease treatment. Acta Pharm Sin B. 2025;15(6):2818\u201344. https:\/\/doi.org\/10.1016\/j.apsb.2025.05.007.","journal-title":"Acta Pharm Sin B"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02383-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02383-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02383-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:27:17Z","timestamp":1791826037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02383-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":242,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2383"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02383-7","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declared no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"237"}}